Skip to main content
AKBA logo

Akebia Therapeutics, Inc. (AKBA) Stock: Price, Forecast & Analyst Target

Akebia Therapeutics, Inc. (AKBA) — MoonshotScore 20/100 (Weak band), calculated Nov 18, 2026. Price $0.4089 (+2.12%), as of the Nov 18, 2026 trading session; market cap $114M.

Educational signal · not a buy or sell recommendation · How to read this

$0.4089 +$0.0085 (+2.12%) Market Cap $114M

Akebia Therapeutics, Inc. · AKBA · NASDAQ

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for kidney diseases. Their lead product candidate, vadadustat, targets anemia due to chronic kidney disease (CKD).

Price as of Nov 18, 2026

Key Statistics

20 of 100

MoonshotScore v2 · Akebia Therapeutics (AKBA)

Weak
Business Quality Solid (60)
Financial Safety Fragile (11)
Valuation Fair (79)
Growth Durability Shrinking (14)
Momentum Slipping (23)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A fragile balance sheet and stalling growth, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Fragile; Valuation: Fair; Growth Durability: Shrinking; Momentum: Slipping.

  • EPS beat 0 of the last 4 reports
  • Altman Z -6.39 · Piotroski F 3

Holding back: balance-sheet strain, soft growth, weak price trend

Helping: an attractive price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for AKBA (57 recorded, newest six shown)
RecordedScoreBand
20Weak
25Weak
21Weak
21Weak
20Weak
20Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.4089
Change on the day+2.12%
52-week range$0.361 – $1.84
Market capitalisation$114M—
Price / earnings (trailing)-5.37
Shares traded on the day7.09M

Price & events

Other perspectives

Council score for Akebia Therapeutics (AKBA): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Negative
Valuation Moderate
Growth Durability Negative
Momentum Weak

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Negative
ROE Negative
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Akebia Therapeutics (AKBA), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Akebia Therapeutics, Inc. (AKBA) is listed on NASDAQ. It employs 194 people and is led by John Butler. The market values it at $114M.

2 · Latest results

What do the latest results show for Akebia Therapeutics (AKBA)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$59M$540,000$0.0020 (diluted)
Q4 FY2025$58M-$12M-$0.05 (diluted)
Q1 FY2026$54M-$9M-$0.03 (diluted)
Q2 FY2026$49M-$9M-$0.03 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Akebia Therapeutics (AKBA)?

Short answer

The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is balance-sheet strain, soft growth, weak price trend. The distress and quality screens read Altman Z -6.39 · Piotroski F 3. Trailing ratios: ROA -3.6% · current ratio 1.36.

Data-derived red flags

  • Listing risk — at $0.4089 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
  • Financial-distress signal — its Altman Z-Score of -6.39 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
4 · What to check next?

What should you watch next at Akebia Therapeutics (AKBA)?

Short answer · as of

Current published price targets run low $1.00 · high $1.00 · consensus $1.00 · median $1.00 against a quoted price of $0.4089 (as of Nov 18, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Akebia Therapeutics compare with its peers?

Short answer

Akebia Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.28 Nov 18, 2026$552M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.02 Nov 18, 2026$255M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
Bristol-Myers Squibb Company (BMY) Named competitor$59.56 Nov 18, 2026$122B85 5-pillar Nov 18, 2026
Amgen Inc. (AMGN) Named competitor$443.89 Nov 18, 2026$240B84 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.96 Nov 18, 2026$186M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.30 Nov 18, 2026$546M68 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.32 Nov 18, 2026$813M63 5-pillar Nov 18, 2026
Akebia Therapeutics (AKBA) — this page$0.4089$114M20

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$1.00 – $1.00
Consensus target
$1.00
Median target
$1.00

Consensus record · Captured .

Measured against a quoted price of $0.4089 (as of Nov 18, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held AKBA in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported AKBA in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Akebia Therapeutics (AKBA)?

Read these with our analysis →

What Investors Ask About Akebia Therapeutics (AKBA)

These answers are editorial: 1 of these 9 answers is drawn from the AKBA research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for AKBA?

AKBA carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for kidney diseases.

Is AKBA a good stock to buy?

Stock Expert AI does not rate AKBA buy, sell or hold. Akebia Therapeutics, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the AKBA stock price today?

The last price recorded for Akebia Therapeutics, Inc. (AKBA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the AKBA price target?

The analyst consensus price target for Akebia Therapeutics, Inc. (AKBA), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What do analysts say about AKBA stock?

Analyst consensus on Akebia Therapeutics, Inc. stock is mixed, reflecting the uncertainty surrounding the regulatory approval and commercial potential of vadadustat.

What are the key factors to evaluate for AKBA?

Akebia Therapeutics, Inc. (AKBA) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Positive Phase III trial results and subsequent regulatory approvals in key markets like the US and EU are critical catalysts. Not financial advice.

How frequently does AKBA data refresh on this page?

AKBA's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven AKBA's recent stock price performance?

Akebia Therapeutics, Inc. (AKBA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Lead product candidate, vadadustat, in Phase III clinical development. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider AKBA overvalued or undervalued right now?

Akebia Therapeutics, Inc. (AKBA) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 10 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.